Products ({{ products.totalElements }})
News & articles ({{ wpNewsAndArticles.total_posts }})
Blog entries ({{ wpBlogEntries.total_posts }})

{{ String(product.attributes.name) }} {{ String(product.attributes.productType) }} - NEW	{{ String(product.attributes.artNo) }}	{{ (String(product.attributes.sizeStr) != 'undefined') ? String(product.attributes.sizeStr) : '–' }}	Not available On Request {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} Login for price

Full search results →

No products found

News {{ news.date \| formatDate }} #{{tag.name}}

No news & articles found

Full search results →

blog entry {{ blogEntry.date \| formatDate }}

No blog entries found

Full search results →

Anti-Hu CD30 FITC

Antibodies Primary

Make a customized order

Article No

AFC-UVNNUN-100

Application

Species Reactivity

human

Size

100 tests

Clone

Ber-H8

Source / Host

mouse

Article No

AFC-UVNNUN-100

Application

Species Reactivity

human

Size

100 tests

Clone

Ber-H8

Source / Host

mouse

Specifications
Suggested protocols
References

Specifications

Application	FC
Article No	AFC-UVNNUN-100
Biosite Brand	Biosite Flow
Country Availability	all
Clone	Ber-H8
Clone Type	monoclonal
Conjugation	FITC
Description	Anti-Hu CD30 FITC
Recommended Dilution	The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
Supplier	Nordic Biosite
Entrez Gene ID	943
Format	FITC
Isotype	IgG1 k
Keywords	CD and Related Antigens (Human)
Notes	CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response.
Alias Names	Ki-1, TNFRSF8, CD30L receptor, D1S166E
Previous Article No	AFC-4925-2
Product Type	Antibodies Primary
Protocol	Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Purification	Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Research area	Immunology
Size	100 tests
Source / Host	mouse
Species Reactivity	human
Storage	Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Substrate / Buffer	Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Technical Specifications	The mouse monoclonal antibody Ber-H8 recognizes extracellular part of CD30 (Ki-1 antigen), a 105 kDa single chain glycoprotein expressed on Hodgkin's and Reed-Sternberg cells; it is also found in Burkitt's lymphomas, virus-infected T and B lymphocytes, and on normal B and T lymphocytes after activation (T lymphocytes that produce Th2-type cytokines and on CD4+/CD8+ T lymphocytes that co-express CD45RO and the IL4 receptor).
UniProt Number	P28908
Product Page Updated	2024-01-03T12:18:20.318Z

Suggested protocols

Flow Cytometry

References

*Aalberse JA, Kapitein B, de Roock S, Klein MR, de Jager W, van der Zee R, Hoekstra MO, van Wijk F, Prakken BJ: Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60). PLoS One. 2011;6(9):e24119., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=aalberse+ja+kapitein+b+de+roock+s ,*Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85(1):1-14., URL: http://www.ncbi.nlm.nih.gov/pubmed/7803786 ,*Berro AI, Perry GA, Agrawal DK: Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004 Aug 1;173(3):2174-83., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=berro+ai+perry+ga ,*Franke AC, Jung D, Ellis TM: Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma. 2000 Feb;19(1):43-8., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=franke+ac+jung+d+ellis+tm ,*Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004 Feb 15;172(4):2186-93., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=matsumoto+k+terakawa+m+miura+k,,*Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007 Apr;282(14):10252-62. , URL: https://www.ncbi.nlm.nih.gov/pubmed/17261581?ordin,*Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007 Mar 1;109(5):2225-33., URL: https://www.ncbi.nlm.nih.gov/pubmed/17068147?ordin,*Kusanovic JP, Romero R, Hassan SS, Gotsch F, Edwin S, Chaiworapongsa T, Erez O, Mittal P, Mazaki-Tovi S, Soto E, Than NG, Friel LA, Yoon BH, Espinoza J: Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med. 2007 Aug 28:1-12, URL: https://www.ncbi.nlm.nih.gov/pubmed/17853188?ordin,*Bekiaris V, Withers D, Glanville SH, McConnell FM, Parnell SM, Kim MY, Gaspal FM, Jenkinson E, Sweet C, Anderson G, Lane PJ: Role of CD30 in B/T segregation in the spleen. J Immunol. 2007 Dec 1;179(11):7535-43., URL: https://www.ncbi.nlm.nih.gov/pubmed/18025198?ordin,*Polte T, Behrendt AK, Hansen G: Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol. 2006 Oct;118(4):942-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/17030250?ordin,*Kennedy MK, Willis CR, Armitage RJ: Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006 Jun;118(2):143-52., URL: https://www.ncbi.nlm.nih.gov/pubmed/16771849?ordin,*Fischer M, Harvima IT, Carvalho RF, Möller C, Naukkarinen A, Enblad G, Nilsson G: Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006 Oct;116(10):2748-56., URL: https://www.ncbi.nlm.nih.gov/pubmed/16964309?ordin,*Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, Roskos M, Serody JS, Yagita H, Podack ER, Taylor PA: CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 2004 Sep 1;173(5):2933-41., URL: https://www.ncbi.nlm.nih.gov/pubmed/15322151?ordin,,

Shipping info

The delivery time for this item is approximately 8-16 business days. Read more